Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice
Popovich, I. G., Voitenkov, B. O., Anisimov, V. N., Ivanov, V. T., Mikhaleva, I. I., Zabezhinski, M. A., Alimova, I. N., Baturin, D. A., Zavarzina, N. Y., Rosenfeld, S. V., Semenchenko, A. V.
, Yashin, A. I.
Mechanisms of Ageing and Development, 124:6, 721–731 (2003)
From the age of 3 months until their natural deaths, female Swiss-derived SHR mice were subcutaneously injected 5 consecutive days every month with 0.1 ml of normal saline (control) or with 2.5 mg/mouse (/100 mg/kg) of delta-sleep inducing peptide (DSIP, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) as the preparation Deltaran† solved in 0.1 ml of saline. There were 54 mice in each group. The results of this study show that the treatment with Deltaran did not influence food consumption, but decreased the body
weight of mice; it slowed down the age-related switching-off of estrous function; it decreased by 22.6% the frequency of chromosome
aberrations in bone marrow cells; it did not influence mean life span; and it increased by 17.1% life span of the last 10% of the survivors and by 24.1% maximum life span in comparison with the control group. We also found that treatment with Deltaran significantly decreased total spontaneous tumor incidence (by 2.6-fold), mainly mammary carcinomas and leukemias in mice as compared with the control group. This is the first report on geroprotector and anticarcinogenic effect of DSIP-containing